Dear NIH-Korean Scientists, We will have the 8th NIH-KSA seminar. Lunch
will be provided by Teraimmune, Inc. We hope to see you there! 여덟번째 NIH-KSA세미나가 다음주 화요일에 있을 예정입니다. Teraimmune,
Inc이 점심 제공합니다. 여러분의 많은 참여 부탁드립니다.
세미나가 끝난후, 매달 점심을 제공해주시는 Psomagen
(previously Macrogen) 에서 5-7분정도 간단한 회사 설명이 있을 예정이니 많은 관심 부탁드립니다. 감사합니다. Time (강연시간): / October 8 (Tue),
12:30-1:30 PM (45 min seminar, 15 min Q&A) 장소: Campus, Building 10, FAES Room
3 - B1C207 SPEAKER INFORMATION Name(성함): Yong
Chan Kim, PhD (김용찬), Jihoon
Park, PhD (박지훈) Position and Department: CEO and COO, TeraImmune, Inc. Seminar Title (강연제목):
- Title: First-in-human clinical study of CAR-Treg
therapy
- Title: Startup, Start-it-up!
Abstract (초록)
- , Inc.
pre-clinical stage immune cell therapeutics company based in Rockville,
Maryland. development of the regulatory T cell
(Treg) therapy in hemophilia A (HA) with FVIII anti-drug antibody
(ADA). FVIII replacement is a standard of care treatment in
HA. However, the formation of anti-FVIII antibody (a.k.a., “FVIII
inhibitor”) is a serious complication in the FVIII-replaced HA
patients. Since Treg therapy has been highlighted as an ideal
approach in controlling immune problem, our team has been dedicated to the
development of Treg therapy specific to HA. By combining the
patented Treg culture method and FVIII-specific TCR, we have successfully
demonstrated the therapeutic concept of FVIII TCR-Treg therapy in
controlling of in hemophilic mice. To translate this
success to the clinic, TeraImmune has been continuing development towards
the first-in-human clinical trial in HA patients with anti-FVIII ADA under
the support of SBIR phase I funding and PACT service program, which
provides the -grade cell product manufacturing and the related
regulatory assistance (sponsored by NHLBI, NIH).
- We will discuss the following
topics: 1) How can scientists bring their and technology into the
market? A case study of TeraImmune. 2) How does startup grow in the US and
in Korea? 3) Why we should jump in the startups now?
|
